4. Issues of Ethnopharmacology in HIV Management
Potential Benefits of Improved Knowledge of Pharmacogenomics
Pharmacogenomics has the potential to allow clinicians to develop individualized drug therapy by assessing each patient’s particular genetic variations that can affect a drug’s efficacy and the risk of adverse events. Future developments in pharmacogenomics could mean:
- Pharmaceutical companies will be able to develop therapies that better target specific diseases, thereby optimizing a drug’s therapeutic effects while decreasing damage to nearby healthy cells.
- Medications may provide faster recovery times and improved safety profiles due to reduced risk of adverse events.
- Today the dosages of drugs typically are either standardized for adults or based on other factors such as weight. Pharmacogenomic-based drug development will take into consideration how a patient’s body processes a drug and the time and mode needed for metabolization.
Known and Potential Impacts of Polymorphisms
Patients often experience variable efficacy and adverse event profiles when receiving antiretroviral therapy. One important factor influencing this variability is an individual’s polymorphisms in proteins related to drug metabolism and transport. Many antiretrovirals are either metabolized by enzymes that can be expressed in variable polymorphisms—eg, the cytochrome P450 (CYP450) and glucuronyl transferase (GT) enzymes or are transported by drug transporters—eg, the ATP-binding cassette (ABC) and solute carrier (SLC) families. One important example is a CYP2B6 genetic variant that is predictive of higher plasma efavirenz exposure and possibly increased central nervous system adverse events. Another strong association between a genetic variant and antiretroviral response involves the hypersensitivity reaction that can occur with the nucleoside reverse transcriptase inhibitor (NRTI) abacavir. In both of these cases, the relevant polymorphisms occur in association with a patient’s racial or ethnic background. [Owen 2006]
Abacavir
One of the most reliable pharmacogenomic tools in managing HIV patients is screening for the HLA-B*5701 allele (a polymorphism in the human leukocyte antigen B [HLA-B] genetic locus) to assess whether a patient is likely to experience abacavir hypersensitivity reaction (HSR). Abacavir HSR is a multiorgan, systemic condition that occurs in approximately 5% to 8% of HIV-positive patients who begin abacavir-containing therapy; life-threatening complications can ensue if abacavir is continued despite progressive symptoms. [Hetherington 2001] Manifestation of abacavir HSR includes signs or symptoms from > 2 of the following groups: [Hetherington 2001]
- Fever
- Rash
- Gastrointestinal
- Constitutional (fatigue, myalgia, generalized malaise)
- Respiratory
Patients who have experienced abacavir HSR should never be rechallenged with abacavir after discontinuation, as this can result in an immediate and potentially fatal reaction. Abacavir is available as:
- As a single agent (Ziagen®)
- In a dual combination tablet with lamivudine (Epzicom®)
- In a triple combination tablet with zidovudine plus lamivudine (Trizivir®)
In clinical trials, abacavir hypersensitivity reaction has been reported in approximately 6% to 8% of white participants and approximately 2% to 3% of African Americans—a significantly lower incidence.[Hetherington 2001, Moyle 2005] Nolan and colleagues reported an incidence of approximately 1% among Asian Americans and approximately 2% in the US Hispanic population.[Nolan 2003] In a multivariate analysis, Symonds and colleagues found that the risk of developing abacavir hypersensitivity was almost 40% lower for individuals of African descent and for antiretroviral-experienced patients.[Symonds 2005] More than 90% of abacavir hypersensitivity reactions occur during the first 6 weeks of therapy, with a median time to symptom onset of 8 to 11 days.[Clay 2002]
Screening recommendations. The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents recommends screening for HLA-B*5701 before starting any patient on an abacavir-containing regimen and that any patient with a positive test for HLA-B*5701 should not receive abacavir.[DHHS Guidelines] Finding of a positive test for HLA-B*5701 should also be documented in the patient’s medical records. Although the HLA-B*5701 test is an excellent screening tool for abacavir hypersensitivity, a negative test does not absolutely eliminate a possible abacavir HSR. The most widely used screening test uses a polymerase chain reaction sequence-specific oligonucleotide probe for the genetic sequences that code for the HLA-B*5701 allele, typically performed on a blood or saliva sample. [Ma 2010] Although the risk for abacavir HSR is significantly higher among HIV-positive white populations, the potential for severe and even fatal results means that practitioners who are committed to providing culturally competent care must order HLA-B*5701 screening for any patient for whom abacavir-containing therapy is be considered.
Efavirenz
An analysis by Haas and colleagues reported the association between 3 polymorphisms in the CYP2B6 enzyme, which is responsible for metabolizing efavirenz, and plasma levels of the drug and the incidence of related adverse events. [Haas 2004] These genetic variants occurred with greater frequency among African Americans. The investigators found that approximately 20% of African Americans in an AIDS Clinical Trials Group (ACTG) study had a genetic polymorphism (CYP2B6 G516T) that slows the metabolism of efavirenz and is therefore associated with a higher risk of adverse central nervous system (CNS) effects. However, it is important to note that this correlation was associated only with the first week of therapy, confirming clinicians’ current knowledge that efavirenz-associated CNS adverse effects generally are short-term.
Clinicians wishing to prescribe efavirenz for African American patients should take particular care to explain both the potential adverse CNS effects to expect (sleep disturbances, dizziness, headache, and depression) and to stress that in a large majority of patients these effects are typically transient. On the other hand, clinicians should not initiate efavirenz treatment in African Americans at a lower dose than the standard one, due to the risk of the emergence of resistance. In addition, these findings do not necessarily mean that clinicians should avoid use of efavirenz in favor of nevirapine or a protease inhibitor in this population, as those agents also have the potential for adverse events, which may be more serious than the CNS symptoms associated with efavirenz.
Atazanavir
The prescribing information for certain antiretrovirals—in particular, stavudine and didanosine—recommends that dosing should be guided by the individual patient’s weight, primarily to minimize risk of adverse events while maintaining efficacy. The approved dosings for antiretrovirals have been determined from the findings of phase 2 and phase 3 clinical trials in which the study populations were primarily white subjects. However, the issue of whether the same antiretrovirals would have different pharmacokinetic profiles when used in patients of other racial and ethnic backgrounds has not been extensively investigated. Such differences may be due to difference in typical body weight as well as pharmacogenomic factors (such as polymorphisms in the uridin-glucoronosyl-transferase 1A1 (UGT1A1) and multidrug resistance 1 (MDR1) genes). [Rodríguez-Nóvoa 2007]
Avihingsanon and colleagues investigated whether the standard dose of boosted atazanavir (atazanavir/ritonavir 300/100 mg) should be reduced in Thai patients, who typically have lower average body weight than US or West European patients.[Avihingsanon 2009] In their study, the participants received atazanavir/ritonavir 200/100 mg instead of the standard dose prescribed in Western populations. The investigators reported that none of the participants showed subtherapeutic atazanavir plasma values at any time during the study, that bilirubin concentration decreased significantly after dose reduction, and that HIV RNA levels remained < 50 copies/mL in all participants. They concluded that atazanavir/ritonavir 200/100 mg once daily (in combination with appropriate backbone antiretrovirals) may be a more appropriate dose for patients of Thai and other Asian ethnicities. American practitioners who are managing HIV-positive patients of Asian descent for whom atazanavir-containing therapy is the preferred approach may wish to consider whether atazanavir/ritonavir 200/100 mg will reduce the risk of hyperbilirubinemia while maintaining virologic suppression. This approach would require very careful clinical monitoring of HIV RNA level and other therapeutic parameters.
Maraviroc
As discussed in Module 2 of the current curriculum, the CCR5 antagonist maraviroc should be used only in patients who have been shown to have R5-only HIV infection. Persons infected with some of the non-B HIV subtypes, which are typically found in certain population groups other than American or West European, may have either higher or lower incidences of CXCR4-tropic virus, meaning that they may be less likely or more likely, respectively, to benefit from maraviroc-containing therapy. For more detailed discussion of these issues and their potential implications for clinical practice, please review Module 2, “HIV Types, Groups, and Clades.”